Cargando…

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study

OBJECTIVE: Gout is associated with lifestyle, body mass index (BMI) and comorbidities, including dyslipidaemia. We studied how in actively treated patients, anthropometric measures and lipid levels changed over 2 years and whether they predicted gout outcomes. METHODS: Patients with a recent gout fl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uhlig, Till, Karoliussen, Lars Fridtjof, Sexton, Joseph, Kvien, Tore K, Haavardsholm, Espen A, Hammer, Hilde Berner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Crystal Arthropathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693886/ http://dx.doi.org/10.1136/rmdopen-2023-003600

Ejemplares similares

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study
por: Uhlig, Till, et al.
Publicado: (2021)

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
por: Uhlig, Till, et al.
Publicado: (2022)

Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective
por: Kapetanovic, Meliha C, et al.
Publicado: (2016)

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
por: Murdoch, Rachel, et al.
Publicado: (2021)

Spontaneous resolution of acute gout: mechanisms and therapeutic targets
por: Shi, Meiling, et al.
Publicado: (2023)

Multiple common and rare variants of ABCG2 cause gout
por: Higashino, Toshihide, et al.
Publicado: (2017)

Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients
por: Nakayama, Akiyoshi, et al.
Publicado: (2020)

Occupational exposure to inorganic dust and risk of gout: a population-based study
por: Sigurdardottir, Valgerdur, et al.
Publicado: (2020)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data
por: Singh, Jasvinder A, et al.
Publicado: (2018)

Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout
por: Kawamura, Yusuke, et al.
Publicado: (2019)

Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout
por: Laurent, Victor, et al.
Publicado: (2023)

Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients
por: Rodríguez-Sosa, Enrique, et al.
Publicado: (2023)

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
por: Uhlig, T., et al.
Publicado: (2022)

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease
por: Cipolletta, Edoardo, et al.
Publicado: (2023)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
por: Pérez Ruiz, Fernando, et al.
Publicado: (2019)

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care
por: Roddy, Edward, et al.
Publicado: (2020)

Relationship between tissue stress during gait in healthy volunteers and patterns of urate deposition and bone erosion in gout: a biomechanical computational modelling study
por: Dalbeth, Nicola, et al.
Publicado: (2015)

Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink
por: Roddy, Edward, et al.
Publicado: (2023)

Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan
por: Koto, Ruriko, et al.
Publicado: (2021)

Diagnostic value of ultrasound in calcium pyrophosphate deposition disease: a systematic review and meta-analysis
por: Gamon, Etienne, et al.
Publicado: (2015)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease
por: Wu, Y, et al.
Publicado: (2016)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
por: Ghang, Byeong-zu, et al.
Publicado: (2022)

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis
por: Krekeler, Martin, et al.
Publicado: (2022)

Case report: crowned dens syndrome in a patient with seronegative rheumatoid arthritis
por: Ferraccioli, Gianfranco, et al.
Publicado: (2023)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
por: Holten, Karen, et al.
Publicado: (2022)

Associations between joint pathologies and central sensitization in persons with hand osteoarthritis: results from the Nor-Hand study
por: Steen Pettersen, Pernille, et al.
Publicado: (2021)

Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort
por: Maugesten, Øystein, et al.
Publicado: (2020)

Correction to: Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort
por: Maugesten, Øystein, et al.
Publicado: (2021)

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ab2c224oa4ltjs2pdvpq6c9m4